Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study
Latest Information Update: 28 Mar 2025
At a glance
- Drugs SHR-1905 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 25 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2025 Status changed from not yet recruiting to recruiting.
- 30 Oct 2023 New trial record